L'intérêt à découvert pour D-Wave Quantum donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de D-Wave Quantum. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

D-Wave Quantum (NYSE:QBTS) Stock, Rapport sur les intérêts à découvert

D-Wave Quantum

D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.

D-Wave Quantum Inc

D-Wave Quantum Inc. Warrants, each whole warrant exercisable for 1.4541326 Common Shares at an exercise price of $11.50

Trane Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Trane Technologies will report an earnings per share (EPS) of $2.20. 
Investors in Trane Technologies are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 0.97% drop in the share price on the subsequent day.
Here's a look at Trane Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.54</td>
<td>3.24</td>
<td>3.08</td>
<td>1.64</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.61</td>
<td>3.37</td>
<td>3.30</td>
<td>1.94</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745935290_0.png" alt="eps graph" />
<h3>Trane Technologies Share Price Analysis</h3>
Shares of Trane Technologies were trading at $351.32 as of April 28. Over the last 52-week period, shares are up 11.32%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Trane Technologies</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Trane Technologies.
Analysts have given Trane Technologies a total of 7 ratings, with the consensus rating being Buy. The average one-year price target is $407.71, indicating a potential 16.05% upside.
<h3>Peer Ratings Comparison</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Johnson Controls Intl, Carrier Global and Lennox Intl, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Johnson Controls Intl, with an average 1-year price target of $93.75, suggesting a potential 73.31% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Carrier Global, with an average 1-year price target of $76.25, suggesting a potential 78.3% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Lennox Intl, with an average 1-year price target of $598.71, suggesting a potential 70.42% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Johnson Controls Intl, Carrier Global and Lennox Intl are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trane Technologies</td>
<td>Buy</td>
<td>10.17%</td>
<td>$1.71B</td>
<td>8.03%</td>
</tr>
<tr>
<td>Johnson Controls Intl</td>
<td>Outperform</td>
<td>4.17%</td>
<td>$1.93B</td>
<td>2.62%</td>
</tr>
<tr>
<td>Carrier Global</td>
<td>Outperform</td>
<td>19.28%</td>
<td>$1.34B</td>
<td>17.73%</td>
</tr>
<tr>
<td>Lennox Intl</td>
<td>Neutral</td>
<td>2.44%</td>
<td>$328.50M</td>
<td>14.13%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Trane Technologies ranks first in revenue growth among its peers. It ranks second in gross profit and return on equity.
<h3>All You Need to Know About Trane Technologies</h3>
Trane Technologies manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its prominent Trane, American Standard, and Thermo King brands. The $20 billion company generates approximately 70% of sales from equipment and 30% from parts and services. While the firm is domiciled in Ireland, North America accounts for over 80% of its revenue.
<h3>Breaking Down Trane Technologies's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Trane Technologies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.17% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 12.4%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Trane Technologies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.03%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Trane Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.64.
<a href="https://www.benzinga.com/quote/TT/earnings">To track all earnings releases for Trane Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Uncovering Potential: Trane Technologies's Earnings Preview

Wells Fargo analyst Stan Berenshteyn maintains GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) with a Overweight and lowers the price target from $8 to $7.

News

Price Target

Analyst Ratings

GDRX

Wells Fargo Maintains Overweight on GoodRx Holdings, Lowers Price Target to $7

In the preceding three months, 6 analysts have released ratings for Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $23.67, with a high estimate of $35.00 and a low estimate of $17.00. This current average has decreased by 7.79% from the previous average price target of $25.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1745935267_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Safehold's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Richard Hill &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $17.00&#x7C;$19.00 &#x7C; 
&#x7C;Haendel St. Juste &#x7C;Mizuho &#x7C;Lowers &#x7C;Neutral &#x7C; $19.00&#x7C;$25.00 &#x7C; 
&#x7C;Richard Anderson &#x7C;Wedbush &#x7C;Maintains &#x7C;Neutral &#x7C; $20.00&#x7C;$20.00 &#x7C; 
&#x7C;Mitch Germain &#x7C;JMP Securities &#x7C;Lowers &#x7C;Market Outperform&#x7C; $32.00&#x7C;$35.00 &#x7C; 
&#x7C;Richard Anderson &#x7C;Wedbush &#x7C;Lowers &#x7C;Neutral &#x7C; $19.00&#x7C;$20.00 &#x7C; 
&#x7C;Mitch Germain &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $35.00&#x7C;$35.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Safehold. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Safehold compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Safehold's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Safehold's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SAFE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Safehold analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Safehold</h2>
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
<h3>Financial Milestones: Safehold's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Safehold faced challenges, resulting in a decline of approximately -10.83% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Safehold's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 28.34%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Safehold's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.12%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.38%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.8.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAFE

6 Analysts Assess Safehold: What You Need To Know

Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Allstate to report an earnings per share (EPS) of $3.76.
Investors in Allstate are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $1.39, which was followed by a 0.59% drop in the share price the next day.
Here's a look at Allstate's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>6.28</td>
<td>2.47</td>
<td>0.37</td>
<td>3.94</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>7.67</td>
<td>3.91</td>
<td>1.61</td>
<td>5.13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745935267_0_0.png" alt="eps graph" />
<h3>Tracking Allstate's Stock Performance</h3>
Shares of Allstate were trading at $195.41 as of April 28. Over the last 52-week period, shares are up 13.63%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/ALL/earnings">To track all earnings releases for Allstate visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Allstate's Future Earnings

Roper Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $624.5, a high estimate of $685.00, and a low estimate of $465.00. This current average reflects an increase of 0.33% from the previous average price target of $622.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1745935258_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Roper Technologies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brad Reback &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $650.00&#x7C;$685.00 &#x7C; 
&#x7C;Joe Vruwink &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $668.00&#x7C;$660.00 &#x7C; 
&#x7C;Stephen Tusa &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $465.00&#x7C;$558.00 &#x7C; 
&#x7C;Brad Reback &#x7C;Stifel &#x7C;Announces &#x7C;Buy &#x7C; $685.00&#x7C;- &#x7C; 
&#x7C;Christopher Glynn &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $640.00&#x7C;$630.00 &#x7C; 
&#x7C;Brian Gesuale &#x7C;Raymond James &#x7C;Raises &#x7C;Strong Buy &#x7C; $655.00&#x7C;$620.00 &#x7C; 
&#x7C;Terry Tillman &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $675.00&#x7C;$665.00 &#x7C; 
&#x7C;Stephen Tusa &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $558.00&#x7C;$539.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Roper Technologies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Roper Technologies compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Roper Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Roper Technologies's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ROP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Roper Technologies analyst ratings.</a>
<h2>All You Need to Know About Roper Technologies</h2>
Roper Technologies is a diversified technology company that operates three segments: application software, network software, and technology enabled products. Roper acquires asset light, cash generative businesses and deploys excess cash to acquire further portfolio companies. The firm operates a highly decentralized model with portfolio company management holding autonomy and accountability for key operational decisions, and a small, centralized team overseeing capital deployment and providing executive coaching and reviewing strategic goals.
<h3>Understanding the Numbers: Roper Technologies's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Roper Technologies's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 16.34%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Roper Technologies's net margin is impressive, surpassing industry averages. With a net margin of 24.63%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Roper Technologies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.47%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Roper Technologies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.47%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.41, Roper Technologies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Roper Technologies: Insights From 8 Financial Analysts

Macro Economic Events

Econ #s

Economics

General

JOLTS Job Openings For March 7.192M Vs 7.490M Est.; 7.480M Prior

Ratings for Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sutro Biopharma, revealing an average target of $1.75, a high estimate of $2.00, and a low estimate of $1.00. This current average has decreased by 78.79% from the previous average price target of $8.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1745935247_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Sutro Biopharma by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Andres Maldonado &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Neutral &#x7C; $2.00&#x7C;$2.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Neutral &#x7C; $2.00&#x7C;$12.00 &#x7C; 
&#x7C;David Nierengarten &#x7C;Wedbush &#x7C;Lowers &#x7C;Neutral &#x7C; $2.00&#x7C;$8.00 &#x7C; 
&#x7C;Tazeen Ahmad &#x7C;B of A Securities &#x7C;Lowers &#x7C;Underperform &#x7C; $1.00&#x7C;$11.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sutro Biopharma. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sutro Biopharma compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Sutro Biopharma's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Sutro Biopharma's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/STRO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sutro Biopharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Sutro Biopharma</h2>
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
<h3>Key Indicators: Sutro Biopharma's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Sutro Biopharma's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -86.98%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -489.18%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -92.98%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -17.27%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Sutro Biopharma's debt-to-equity ratio stands notably higher than the industry average, reaching 0.52. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STRO

Demystifying Sutro Biopharma: Insights From 4 Analyst Reviews

In the current session, Nucor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) is trading at $114.38, after a 1.88% decrease. Over the past month, the stock decreased by 4.42%, and in the past year, by 32.19%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1745935236_0.png" alt="Past Year Chart" />

<h3>Comparing Nucor P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 47.68 in the Metals &amp; Mining industry, Nucor Inc. has a lower P/E ratio of 13.78. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745935236_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for Nucor

Ratings for Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) were provided by 17 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Eastman Chemical, presenting an average target of $104.59, a high estimate of $128.00, and a low estimate of $76.00. A 8.21% drop is evident in the current average compared to the previous average price target of $113.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1745935235_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Eastman Chemical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Michael Leithead &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $85.00&#x7C;$108.00 &#x7C; 
&#x7C;Duffy Fischer &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $87.00&#x7C;$112.00 &#x7C; 
&#x7C;Aleksey Yefremov &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $106.00&#x7C;$120.00 &#x7C; 
&#x7C;Vincent Andrews &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $115.00&#x7C;$125.00 &#x7C; 
&#x7C;Jeffrey Zekaukas &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $76.00&#x7C;$112.00 &#x7C; 
&#x7C;Aleksey Yefremov &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $120.00&#x7C;$128.00 &#x7C; 
&#x7C;Michael Sison &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $90.00&#x7C;$125.00 &#x7C; 
&#x7C;Joshua Spector &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $115.00&#x7C;$123.00 &#x7C; 
&#x7C;Charles Neivert &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $99.00&#x7C;$105.00 &#x7C; 
&#x7C;Patrick Cunningham &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $101.00&#x7C;$105.00 &#x7C; 
&#x7C;John Roberts &#x7C;Mizuho &#x7C;Maintains &#x7C;Outperform &#x7C; $105.00&#x7C;$105.00 &#x7C; 
&#x7C;Charles Neivert &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $105.00&#x7C;$102.00 &#x7C; 
&#x7C;Arun Viswanathan &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $103.00&#x7C;$101.00 &#x7C; 
&#x7C;Jeffrey Zekaukas &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $112.00&#x7C;$110.00 &#x7C; 
&#x7C;Michael Leithead &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $108.00&#x7C;$111.00 &#x7C; 
&#x7C;Aleksey Yefremov &#x7C;Keybanc &#x7C;Raises &#x7C;Overweight &#x7C; $128.00&#x7C;$121.00 &#x7C; 
&#x7C;Joshua Spector &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $123.00&#x7C;$124.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Eastman Chemical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Eastman Chemical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Eastman Chemical's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Eastman Chemical analyst ratings.</a>
<h2>All You Need to Know About Eastman Chemical</h2>
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
<h3>Financial Insights: Eastman Chemical</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Eastman Chemical's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -0.87%. This indicates a decrease in top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Eastman Chemical's net margin is impressive, surpassing industry averages. With a net margin of 7.95%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Eastman Chemical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.12% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.21%, the company showcases effective utilization of assets.
Debt Management: Eastman Chemical's debt-to-equity ratio is below the industry average at 0.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 17 Analysts Discuss Eastman Chemical Stock

AZZ's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) short percent of float has risen 5.79% since its last report. The company recently reported that it has 812 thousand shares sold short, which is 4.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AZZ Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745935228_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AZZ has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing AZZ's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AZZ's peer group average for short interest as a percentage of float is 4.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About AZZ?

Masimo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NYSE">MASI</a>) short percent of float has fallen 3.59% since its last report. The company recently reported that it has 2.79 million shares sold short, which is 7.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Masimo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745935223_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Masimo has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Masimo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Masimo's peer group average for short interest as a percentage of float is 4.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MASI

Is the Market Bullish or Bearish on Masimo?

During the last three months, 6 analysts shared their evaluations of Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $498.17, a high estimate of $619.00, and a low estimate of $409.00. A 5.92% drop is evident in the current average compared to the previous average price target of $529.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1745935220_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Strategy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mike Colonnese &#x7C;HC Wainwright &amp; Co. &#x7C;Announces &#x7C;Buy &#x7C; $480.00&#x7C;- &#x7C; 
&#x7C;Ramsey El-Assal &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $421.00&#x7C;$515.00 &#x7C; 
&#x7C;Bill Papanastasiou &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Announces &#x7C;Outperform &#x7C; $560.00&#x7C;- &#x7C; 
&#x7C;Matthew Galinko &#x7C;Maxim Group &#x7C;Raises &#x7C;Buy &#x7C; $500.00&#x7C;$480.00 &#x7C; 
&#x7C;Brett Knoblauch &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Overweight &#x7C; $619.00&#x7C;$613.00 &#x7C; 
&#x7C;Joseph Vafi &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $409.00&#x7C;$510.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Strategy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Strategy compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Strategy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Strategy's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MSTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Strategy analyst ratings.</a>
<h2>Get to Know Strategy Better</h2>
Strategy is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provide industry AI-powered enterprise analytics software.
<h3>Strategy: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Strategy's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -3.04% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Strategy's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -555.78%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -6.1%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Strategy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.92%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.4, Strategy adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MSTR

Analyst Expectations For Strategy's Future

Nucor's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) short percent of float has risen 9.8% since its last report. The company recently reported that it has 5.86 million shares sold short, which is 3.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Nucor Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745935216_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nucor has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Nucor's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Nucor's peer group average for short interest as a percentage of float is 5.97%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Nucor?

Across the recent three months, 16 analysts have shared their insights on Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Illumina, revealing an average target of $127.06, a high estimate of $247.00, and a low estimate of $77.00. This current average has decreased by 15.4% from the previous average price target of $150.19. 
<img src="https://www.benzinga.com/files/images/story/2025/1745935210_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Illumina. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $92.00&#x7C;$115.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $77.00&#x7C;$100.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $112.00&#x7C;$128.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $85.00&#x7C;$90.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $128.00&#x7C;$247.00 &#x7C; 
&#x7C;Mason Carrico &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $156.00&#x7C;$156.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $115.00&#x7C;$135.00 &#x7C; 
&#x7C;Catherine Ramsey &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$127.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$130.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $136.00&#x7C;$150.00 &#x7C; 
&#x7C;David Westenberg &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $190.00&#x7C;$185.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $100.00&#x7C;$130.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $247.00&#x7C;$250.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $135.00&#x7C;$145.00 &#x7C; 
&#x7C;Subbu Nambi &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $150.00&#x7C;$170.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $130.00&#x7C;$145.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Illumina. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Illumina's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Illumina's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Discovering Illumina: A Closer Look</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>Understanding the Numbers: Illumina's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Illumina's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -1.6%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Illumina's net margin excels beyond industry benchmarks, reaching 16.94%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Illumina's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.31% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Illumina's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.04%, the company showcases efficient use of assets and strong financial health.
Debt Management: Illumina's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ILMN

Assessing Illumina: Insights From 16 Financial Analysts

CB Consumer Confidence (Apr) 86 vs 87.7 Est.

Wells Fargo analyst Elyse Greenspan maintains Principal Financial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) with a Underweight and raises the price target from $68 to $69.

Wells Fargo Maintains Underweight on Principal Financial Group, Raises Price Target to $69

Wells Fargo analyst Jonathan Reeder maintains SJW Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NASDAQ">SJW</a>) with a Equal-Weight and raises the price target from $57 to $60.

Wells Fargo Maintains Equal-Weight on SJW Gr, Raises Price Target to $60

WIIM

BYON

BYON stock has given up its prior gain. Beyond shares were trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Wells Fargo analyst Zachary Fadem maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Equal-Weight and raises the price target from $445 to $465.

Wells Fargo Maintains Equal-Weight on Domino's Pizza, Raises Price Target to $465

Tigress Financial analyst Ivan Feinseth maintains AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) with a Buy and raises the price target from $32 to $34.

Comments

D-Wave Quantum

Intérêt court

D-Wave Quantum (NYSE:QBTS) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL